http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 15 Jul 2026 19:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+Jul+13++Filed+by%3A+Borie+Dominique+Christian/26775161.html si-local-file:///var/storage/secattach/20260715/26775161.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+Jul+13++Filed+by%3A+Borie+Dominique+Christian/26775161.html Wed, 15 Jul 2026 19:00:00 -0400 CUE O.31243297 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+Jul+13++Filed+by%3A+Borie+Dominique+Christian/26775161.html si-local-file:///var/storage/secattach/20260715/26775161.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+Jul+13++Filed+by%3A+Borie+Dominique+Christian/26775161.html Wed, 15 Jul 2026 19:00:00 -0400 CUE O.31243297 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+Jul+13++Filed+by%3A+Borie+Dominique+Christian/26775157.html si-local-file:///var/storage/secattach/20260715/26775157.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+Jul+13++Filed+by%3A+Borie+Dominique+Christian/26775157.html Wed, 15 Jul 2026 18:58:00 -0400 CUE O.31243297 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+Jul+13++Filed+by%3A+Borie+Dominique+Christian/26775157.html si-local-file:///var/storage/secattach/20260715/26775157.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Cue+Biopharma%2C+Inc.+++++++For%3A+Jul+13++Filed+by%3A+Borie+Dominique+Christian/26775157.html Wed, 15 Jul 2026 18:58:00 -0400 CUE O.31243297 http://www.streetinsider.com/Management+Changes/Cue+Biopharma+names+Dominic+Borie+as+CMO+and+R%26D+head/26760285.html <p>Cue Biopharma, Inc. (Nasdaq: CUE) has appointed Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development, according to a company statement. He will report to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Borie brings more than two decades of experience in biotechnology and pharmaceutical research and clinical development. Most recently, he served as Strategic Advisor to the CEO and Board of Kyverna Therapeutics, where he previously held roles as President of Research & Development and founding Chief Executive Officer. Earlier positions include senior leadership roles at Horizon Therapeutics, Genentech, Amgen, and Roche. Before entering http://www.streetinsider.com/Management+Changes/Cue+Biopharma+names+Dominic+Borie+as+CMO+and+R%26D+head/26760285.html Mon, 13 Jul 2026 08:31:07 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Management+Changes/Cue+Biopharma+names+Dominic+Borie+as+CMO+and+R%26D+head/26760285.html <p>Cue Biopharma, Inc. (Nasdaq: CUE) has appointed Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development, according to a company statement. He will report to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Borie brings more than two decades of experience in biotechnology and pharmaceutical research and clinical development. Most recently, he served as Strategic Advisor to the CEO and Board of Kyverna Therapeutics, where he previously held roles as President of Research & Development and founding Chief Executive Officer. Earlier positions include senior leadership roles at Horizon Therapeutics, Genentech, Amgen, and Roche. Before entering http://www.streetinsider.com/Management+Changes/Cue+Biopharma+names+Dominic+Borie+as+CMO+and+R%26D+head/26760285.html Mon, 13 Jul 2026 08:31:07 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Management+Changes/Cue+Biopharma+names+Dominic+Borie+as+CMO+and+R%26D+head/26760285.html <p>Cue Biopharma, Inc. (Nasdaq: CUE) has appointed Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development, according to a company statement. He will report to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Borie brings more than two decades of experience in biotechnology and pharmaceutical research and clinical development. Most recently, he served as Strategic Advisor to the CEO and Board of Kyverna Therapeutics, where he previously held roles as President of Research & Development and founding Chief Executive Officer. Earlier positions include senior leadership roles at Horizon Therapeutics, Genentech, Amgen, and Roche. Before entering http://www.streetinsider.com/Management+Changes/Cue+Biopharma+names+Dominic+Borie+as+CMO+and+R%26D+head/26760285.html Mon, 13 Jul 2026 08:31:07 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Management+Changes/Cue+Biopharma+names+Dominic+Borie+as+CMO+and+R%26D+head/26760285.html <p>Cue Biopharma, Inc. (Nasdaq: CUE) has appointed Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development, according to a company statement. He will report to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Borie brings more than two decades of experience in biotechnology and pharmaceutical research and clinical development. Most recently, he served as Strategic Advisor to the CEO and Board of Kyverna Therapeutics, where he previously held roles as President of Research & Development and founding Chief Executive Officer. Earlier positions include senior leadership roles at Horizon Therapeutics, Genentech, Amgen, and Roche. Before entering http://www.streetinsider.com/Management+Changes/Cue+Biopharma+names+Dominic+Borie+as+CMO+and+R%26D+head/26760285.html Mon, 13 Jul 2026 08:31:07 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Management+Changes/Cue+Biopharma+names+Dominic+Borie+as+CMO+and+R%26D+head/26760285.html <p>Cue Biopharma, Inc. (Nasdaq: CUE) has appointed Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development, according to a company statement. He will report to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Borie brings more than two decades of experience in biotechnology and pharmaceutical research and clinical development. Most recently, he served as Strategic Advisor to the CEO and Board of Kyverna Therapeutics, where he previously held roles as President of Research & Development and founding Chief Executive Officer. Earlier positions include senior leadership roles at Horizon Therapeutics, Genentech, Amgen, and Roche. Before entering http://www.streetinsider.com/Management+Changes/Cue+Biopharma+names+Dominic+Borie+as+CMO+and+R%26D+head/26760285.html Mon, 13 Jul 2026 08:31:07 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Management+Changes/Cue+Biopharma+names+Dominic+Borie+as+CMO+and+R%26D+head/26760285.html <p>Cue Biopharma, Inc. (Nasdaq: CUE) has appointed Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development, according to a company statement. He will report to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Borie brings more than two decades of experience in biotechnology and pharmaceutical research and clinical development. Most recently, he served as Strategic Advisor to the CEO and Board of Kyverna Therapeutics, where he previously held roles as President of Research & Development and founding Chief Executive Officer. Earlier positions include senior leadership roles at Horizon Therapeutics, Genentech, Amgen, and Roche. Before entering http://www.streetinsider.com/Management+Changes/Cue+Biopharma+names+Dominic+Borie+as+CMO+and+R%26D+head/26760285.html Mon, 13 Jul 2026 08:31:07 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Management+Changes/Cue+Biopharma+names+Dominic+Borie+as+CMO+and+R%26D+head/26760285.html <p>Cue Biopharma, Inc. (Nasdaq: CUE) has appointed Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development, according to a company statement. He will report to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Borie brings more than two decades of experience in biotechnology and pharmaceutical research and clinical development. Most recently, he served as Strategic Advisor to the CEO and Board of Kyverna Therapeutics, where he previously held roles as President of Research & Development and founding Chief Executive Officer. Earlier positions include senior leadership roles at Horizon Therapeutics, Genentech, Amgen, and Roche. Before entering http://www.streetinsider.com/Management+Changes/Cue+Biopharma+names+Dominic+Borie+as+CMO+and+R%26D+head/26760285.html Mon, 13 Jul 2026 08:31:07 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Management+Changes/Cue+Biopharma+names+Dominic+Borie+as+CMO+and+R%26D+head/26760285.html <p>Cue Biopharma, Inc. (Nasdaq: CUE) has appointed Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development, according to a company statement. He will report to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Borie brings more than two decades of experience in biotechnology and pharmaceutical research and clinical development. Most recently, he served as Strategic Advisor to the CEO and Board of Kyverna Therapeutics, where he previously held roles as President of Research & Development and founding Chief Executive Officer. Earlier positions include senior leadership roles at Horizon Therapeutics, Genentech, Amgen, and Roche. Before entering http://www.streetinsider.com/Management+Changes/Cue+Biopharma+names+Dominic+Borie+as+CMO+and+R%26D+head/26760285.html Mon, 13 Jul 2026 08:31:07 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html <p>BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research &amp; Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html Mon, 13 Jul 2026 08:30:00 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html <p>BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research &amp; Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html Mon, 13 Jul 2026 08:30:00 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html <p>BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research &amp; Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html Mon, 13 Jul 2026 08:30:00 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html <p>BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research &amp; Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html Mon, 13 Jul 2026 08:30:00 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html <p>BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research &amp; Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html Mon, 13 Jul 2026 08:30:00 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html <p>BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research &amp; Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html Mon, 13 Jul 2026 08:30:00 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html <p>BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research &amp; Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html Mon, 13 Jul 2026 08:30:00 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html <p>BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research &amp; Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of http://www.streetinsider.com/Press+Releases/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html Mon, 13 Jul 2026 08:30:00 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Globe+Newswire/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html <p>BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research &amp; Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of http://www.streetinsider.com/Globe+Newswire/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html Mon, 13 Jul 2026 08:30:00 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Globe+Newswire/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html <p>BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research &amp; Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of http://www.streetinsider.com/Globe+Newswire/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html Mon, 13 Jul 2026 08:30:00 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Globe+Newswire/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html <p>BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research &amp; Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of http://www.streetinsider.com/Globe+Newswire/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html Mon, 13 Jul 2026 08:30:00 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Globe+Newswire/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html <p>BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research &amp; Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of http://www.streetinsider.com/Globe+Newswire/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html Mon, 13 Jul 2026 08:30:00 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133 http://www.streetinsider.com/Globe+Newswire/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html <p>BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research &amp; Development. He reports to President and Chief Executive Officer Shao-Lee Lin, M.D., Ph.D.</p> <p>Dr. Borie joins Cue as the company continues to execute its strategy of identifying and advancing through development those immunology programs with potential to offer clinically meaningful improvements for patients. Cue expects Phase 2 CSU data readout for the CUE-221 program by end of http://www.streetinsider.com/Globe+Newswire/Cue+Biopharma+Appoints+Dominic+Borie%2C+M.D.%2C+Ph.D.%2C+as+Chief+Medical+Officer+and+Head+of+Research+%26amp%3B+Development/26760264.html Mon, 13 Jul 2026 08:30:00 -0400 A.11608963 A.26756439 A.40151759 CUE O.00050368 O.05010326 O.31243297 O.45210133